Amicus Therapeutics, Inc. (FOLD) Shares Bought by Candriam Luxembourg S.C.A.

Candriam Luxembourg S.C.A. boosted its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 12.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 540,400 shares of the biopharmaceutical company’s stock after buying an additional 58,000 shares during the quarter. Candriam Luxembourg S.C.A. owned 0.33% of Amicus Therapeutics worth $7,776,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Amalgamated Bank raised its position in Amicus Therapeutics by 5.7% during the 2nd quarter. Amalgamated Bank now owns 18,451 shares of the biopharmaceutical company’s stock worth $186,000 after buying an additional 1,002 shares during the last quarter. Great West Life Assurance Co. Can raised its position in Amicus Therapeutics by 40.2% during the 3rd quarter. Great West Life Assurance Co. Can now owns 14,445 shares of the biopharmaceutical company’s stock worth $212,000 after buying an additional 4,145 shares during the last quarter. California Public Employees Retirement System raised its position in Amicus Therapeutics by 2.4% during the 3rd quarter. California Public Employees Retirement System now owns 181,000 shares of the biopharmaceutical company’s stock worth $2,729,000 after buying an additional 4,200 shares during the last quarter. Strs Ohio purchased a new position in Amicus Therapeutics during the 3rd quarter worth approximately $102,000. Finally, Teachers Advisors LLC raised its position in Amicus Therapeutics by 3.2% during the 2nd quarter. Teachers Advisors LLC now owns 261,545 shares of the biopharmaceutical company’s stock worth $2,634,000 after buying an additional 8,046 shares during the last quarter.

Amicus Therapeutics, Inc. (NASDAQ FOLD) opened at $15.68 on Thursday. The company has a current ratio of 6.32, a quick ratio of 6.22 and a debt-to-equity ratio of 0.39. Amicus Therapeutics, Inc. has a 1-year low of $5.87 and a 1-year high of $17.40.

FOLD has been the subject of a number of recent research reports. BidaskClub raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, December 27th. Cowen reissued a “buy” rating and set a $22.00 price target on shares of Amicus Therapeutics in a research report on Wednesday, January 10th. Robert W. Baird set a $20.00 price target on shares of Amicus Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, February 7th. ValuEngine raised shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, Zacks Investment Research raised shares of Amicus Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, January 17th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $19.06.

In other news, CEO John F. Crowley sold 5,920 shares of Amicus Therapeutics stock in a transaction that occurred on Friday, December 29th. The shares were sold at an average price of $14.75, for a total transaction of $87,320.00. Following the completion of the transaction, the chief executive officer now directly owns 341,051 shares of the company’s stock, valued at approximately $5,030,502.25. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Jay Barth sold 20,000 shares of Amicus Therapeutics stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $16.80, for a total transaction of $336,000.00. Following the transaction, the insider now directly owns 105,409 shares of the company’s stock, valued at $1,770,871.20. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 250,390 shares of company stock valued at $3,620,581. Insiders own 3.40% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Amicus Therapeutics, Inc. (FOLD) Shares Bought by Candriam Luxembourg S.C.A.” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://ledgergazette.com/2018/02/15/amicus-therapeutics-inc-fold-shares-bought-by-candriam-luxembourg-s-c-a.html.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply